Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.36 |
| ▸ | GSTM2 | P28161 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31260451 | 0.94 | SMN1; SMN2 (0.47) | L3MBTL1MAPTMAPK1NPSR1TDP1 | |
| SCHEMBL31260341 | 0.88 | TSHR (0.45) | MAPK1TDP1CYP3A4TSHRATM | |
| SCHEMBL31260443 | 0.86 | CYP3A4 (0.43) | MAPK1TDP1CYP3A4TSHRATM | |
| SCHEMBL31260295 | 0.84 | CYP3A4 (0.43) | MAPTMAPK1TDP1CYP3A4TSHR | |
| SCHEMBL10239305 | 0.82 | CYP3A4 (0.46) | L3MBTL1MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL31260302 | 0.81 | TSHR (0.45) | MAPTMAPK1TDP1CYP3A4TSHR | |
| SCHEMBL1390827 | 0.80 | ALDH1A1 (0.46) | MAPTMAPK1TDP1CYP3A4TSHR | |
| SCHEMBL31260338 | 0.80 | CYP3A4 (0.42) | MAPK1TDP1CYP3A4TSHRATM | |
| SCHEMBL31260336 | 0.80 | CYP3A4 (0.42) | MAPK1TDP1CYP3A4TSHRATM | |
| SCHEMBL31260306 | 0.79 | ALDH1A1 (0.38) | L3MBTL1MAPTTDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2024240726-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | L3MBTL1 1663/4885MAPT 4827/4885MAPK1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.